Related Experiment Video
Updated: May 27, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Eslicarbazepine acetate for partial-onset seizures
Markus Rauchenzauner1, Gerhard Luef
1Department of Pediatrics, Saint Vincent Hospital Zams, Austria. markus_rauchenzauner@hotmail.com
Eslicarbazepine acetate (ESL) shows efficacy and tolerability as an add-on therapy for adults with partial-onset seizures. Further research is needed to establish its therapeutic value in children and adolescents.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Eslicarbazepine acetate (ESL) is a novel voltage-gated sodium channel blocker.
- ESL is chemically related to carbamazepine and a metabolite of oxcarbazepine.
- Previous studies suggest efficacy and tolerability of ESL in adults with drug-resistant partial-onset seizures.
Purpose of the Study:
- To evaluate the efficacy and tolerability of ESL as an add-on therapy for partial-onset seizures.
- To assess ESL's potential as an alternative antiepileptic drug therapy.
Main Methods:
- Review of Phase II and III studies on ESL in adult patients.
- Analysis of efficacy and tolerability data in pediatric populations.
- Dose-response assessment for seizure frequency reduction and adverse effects.
Main Results:
- ESL 800 and 1200 mg once daily demonstrated efficacy and tolerability in adults.
- Pediatric data indicate a dose-dependent decrease in seizure frequency.
- Common adverse effects in children include dizziness, somnolence, headache, diplopia, nausea, and vomiting.
Conclusions:
- ESL presents a viable alternative for adjunctive therapy in adult drug-resistant partial seizures due to its dosing convenience and profile.
- Ongoing clinical trials are necessary to confirm ESL's efficacy and safety in pediatric and adolescent populations.
- The therapeutic value of ESL in younger patients requires further establishment.
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Glutamate Antagonists
